Abstract. Background-Short chain fatty acid (SCFA) deficiency is associated with colitis in animals and humans, and the mucosal metabolism of these compounds is decreased in ulcerative colitis. Aims-To assess the efficacy of topical SCFA treatment in ulcerative colitis. Patients and Methods-103 patients with distal ulcerative colitis were entered into a six week, double-blind, placebo controlled trial of rectal SCFA twice daily; patients who were unchanged on placebo were offered SCFA in an open-label extension trial. Results-Of the 91 patients completing the trial, more patients in the SCFA treated than in the placebo treated group improved (33% v 20%, p=0 14, NS). Those on SCFA also had larger, but statistically non-significant, reductions in every component of their clinical and histological activity scores. In patients with a relatively short current episode of colitis (<6 months, n=42), more responded to SCFA than to placebo (48% v 18%, p=003). These patients also had larger, but statistically non-significant, decreases in their clinical activity index (p=0.08 v placebo). Every patient who improved used at least five of six of the prescribed rectal SCFA irrigations, whereas only 37% who did not improve were as compliant. In the open-label extension trial, 65% improved on SCFA; these patients also had significant reductions (p<0.02) in their clinical and histological activity scores. Conclusions-Although SCFA enemas were not of therapeutic value in this controlled trial, the results suggest efficacy in subsets of patients with distal ulcerative colitis including those with short active episodes. Prolonged contact with rectal mucosa seems to be necessary for therapeutic benefit. (Gut 1997; 40: 485-491) Keywords: short chain fatty acids, distal ulcerative colitis.
Abstract. Background-Short chain fatty acid (SCFA) deficiency is associated with colitis in animals and humans, and the mucosal metabolism of these compounds is decreased in ulcerative colitis. Aims-To assess the efficacy of topical SCFA treatment in ulcerative colitis. Patients and Methods-103 patients with distal ulcerative colitis were entered into a six week, double-blind, placebo controlled trial of rectal SCFA twice daily; patients who were unchanged on placebo were offered SCFA in an open-label extension trial. Results-Of the 91 patients completing the trial, more patients in the SCFA treated than in the placebo treated group improved (33% v 20%, p=0 14, NS). Those on SCFA also had larger, but statistically non-significant, reductions in every component of their clinical and histological activity scores. In patients with a relatively short current episode of colitis (<6 months, n=42), more responded to SCFA than to placebo (48% v 18%, p=003). These patients also had larger, but statistically non-significant, decreases in their clinical activity index (p=0.08 v placebo). Every patient who improved used at least five of six of the prescribed rectal SCFA irrigations, whereas only 37% who did not improve were as compliant. In the open-label extension trial, 65% improved on SCFA; these patients also had significant reductions (p<0.02) in their clinical and histological activity scores. Conclusions-Although SCFA enemas were not of therapeutic value in this controlled trial, the results suggest efficacy in subsets of patients with distal ulcerative colitis including those with short active episodes. Prolonged contact with rectal mucosa seems to be necessary for therapeutic benefit. Treatment of distal ulcerative colitis consists mainly of topical or oral 5-aminosalicylic acid (5-ASA) compounds or corticosteroids, or both. These compounds alter the inflammatory response by decreasing oxygen free radical activity and proinflammatory cytokine release, and by modifying the lipo-and cyclooxygenase pathways of arachidonic acid metabolism.' They are relatively expensive, not uniformly effective, are not free of undesired systemic effects even in their new formulations,2 and repeated treatment courses are often needed. Short chain fatty acids (SCFA) have been proposed as an inexpensive alternative topical treatment for distal ulcerative colitis.3 Acetate, propionate and butyrate are the predominant ions in faecal water4 and provide most of the metabolic energy for normal colonic epithelial cells. 5 When SCFA are completely absent, diversion colitis develops in humans and experimental animals. 6 For those who did not improve, the code was broken immediately after the final evaluation.
Placebo treated patients in this group were offered SCFA enemas in a six week, open-label extension trial, using the same protocol as described earlier. Protocols were approved by the Institutional Review Board of each participating institution, and all patients gave informed consent.
In the double-blind study, baseline comparisons of treatment groups were performed using the x2 test or the two sample t test. '3 Global assessment was compared between treatment groups using the Mantel-Haenszel test adjusting for centre. ' The purpose of this interim analysis was to estimate treatment differences and to update the initial calculations of statistical power. Therefore, no adjustment to the criterion for significance is made in the final analyses. A sample size of 45 analysable patients per group had 80% power to detect a mean difference of 1 8 in DAI change between the active treatment and control groups. Statistical significance is indicated when p<0 05. All tests were two-tailed.
In assessing outcome, no adjustment for covariates other than clinical centre were made for three reasons. First, there were no statistically significant differences between the SCFA and placebo groups for any baseline covariate. Second, although some covariates were observed to be related to change in disease status as measured by a global response (see Results), these relations were seen only in one of the two study groups. Third, none of these covariates altered the conclusions regarding treatment effect -that is, only minimal changes to the p values for treatment occurred when they were adjusted for.
The baseline characteristics in Table I Stool frequency :p values by analysis of covariance comparing pre-to post-treatment changes between the two groups.
CI=confidence interval.
The distribution of global assessments at the end of the six week trial is shown in Table II . More SCFA treated patients (40%) showed some improvement (complete remission/much improved/minimally improved) than those randomised to placebo (33%, p=0 44, NS).
This difference was greater when we considered substantial improvement only (complete remission/much improved) as treatment response (33% v 20%, p=0-14, NS). Within both the SCFA and placebo groups, except for stool frequency in the latter, the scores for each component and the composite DAI improved significantly between the beginning and the end of the study (Table IH) . Although SCFA treated patients improved more in each measurement and the decrease in the DAI was almost twice that for placebo, none of the differences in the pre-to post-treatment changes between the groups was statistically significant. The mean total histology score for SCFA treated patients improved slightly during the trial, whereas that for the placebo group worsened (Table III) ; neither trend was statistically significant. For SCFA treated patients, there was some minor improvement in three of four components of that score (p=0-05 for mucin depletion), whereas for placebo treated patients, all components showed some deterioration (p=NS for each). For mucin depletion, the difference in pre-to post-treatment change between SCFA and placebo treated patients was statistically significant (p=0-03).
To determine whether any baseline characteristic influenced outcome, we evaluated the relation between each factor in Table I and treatment response. Short duration of current colitis attack (<6 months), baseline disease activity and sex were related to global response in the SCFA group only (Table IV) . Multiple logistic regression analysis indicated that all three factors contributed independently to response -that is, each was significant (p<0-05) in the model with all three factors. However, on direct comparison between SCFA and placebo treated patients within each subgroup, only short duration of current colitis attack seemed to influence treatment outcome significantly (Table IV) .
Responses to prior medications were available in only about two-thirds of our study group. Among these, only 33% of those who had tried rectal 5-ASA and 34% of those who had tried rectal steroids had ever responded to these medications.
Compliance with the enema protocol was poor. Only 28 Much improved 4 24 Minimally improved 3 18 No change 6 35 Complete remission+much improved+minimally improved= 1 (Table VI) . Their histology indexes also improved by the six week end point (Table VI) . Figure 1 shows the components of their DAI responses and Figure 2 patients. 
